PI3K

Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that catalyze the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) to generate the second messenger phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P₃). The production of PI(3,4,5)P₃ facilitates the recruitment and activation of pleckstrin homology (PH) domain–containing proteins at the plasma membrane, thereby initiating downstream signaling cascades essential for cellular proliferation, survival, and migration.

PI3Ks are divided into three major classes, among which Class I PI3Ks are most prominently implicated in cancer biology. Class I enzymes comprise four distinct catalytic isoforms: PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ.

Class IA PI3Ks, the subclass most commonly associated with oncogenic signaling, function as heterodimeric lipid kinases composed of a catalytic p110 subunit (p110α, p110β, or p110δ, encoded by PIK3CA, PIK3CB, and PIK3CD, respectively) and a regulatory p85 subunit.

The PI3K signaling pathway plays a central role in diverse biological processes, including cell cycle progression, cellular growth, survival, actin cytoskeletal rearrangement, migration, and intracellular vesicular trafficking.

Frequently Asked Questions
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate phosphatidylinositol lipids to regulate cell growth, survival, metabolism, and immune signaling. PI3K activation leads to downstream AKT and mTOR pathway signaling. Aberrant PI3K signaling is frequently observed in cancer due to PIK3CA mutations, PTEN loss, or receptor tyrosine kinase activation.
Class I PI3Ks include four catalytic isoforms: PI3Kα (PIK3CA) PI3Kβ (PIK3CB) PI3Kδ (PIK3CD) PI3Kγ (PIK3CG) PI3Kα and β are broadly expressed, while PI3Kδ and γ are enriched in leukocytes and play critical roles in immune regulation. Isoform selectivity is an important consideration in drug development due to toxicity and immune effects.
PI3K inhibitors can be classified as: Pan-PI3K inhibitors Isoform-selective inhibitors (α, β, δ, γ) Dual PI3K/mTOR inhibitors Irreversible inhibitors Selectivity influences therapeutic window and toxicity profile.
While PI3K inhibitors block upstream lipid kinase activity, mTOR inhibitors act downstream at the level of mTORC1 or mTORC2. Dual PI3K/mTOR inhibitors target both nodes of the pathway and may achieve broader pathway suppression.

Items 326-350 of 411

  • PI3K-IN-18 dihydrochloride
    Cat. No.
    A79814

    PI3K-IN-18 dihydrochloride

    PI3K-IN-18 dihydrochloride is a selective inhibitor of the PI3K p110α isoform, derived from a 4-morpholino-2-phenylquinazoline structure. This compound demonstrates significant biological activity in attenuating the PI3K signaling pathway, which plays a crucial role in cell growth, proliferation, and survival. Research applications include cancer biology, where modulation of PI3K activity can provide insights into tumor progression and therapeutic responses.

    1 mg
    $190.00
    5 mg
    $485.00
    All 3 sizes
  • (S)-GSK-F1
    Cat. No.
    A79815

    (S)-GSK-F1

    (S)-GSK-F1 is a potent inhibitor of type III phosphatidylinositol 4-kinase α (PI4KIIIα). It demonstrates inhibitory activity against various kinases, including PI4Kα, PI4Kβ, PI4Kγ, PI3Kα, PI3Kβ, and PI3Kδ, with pIC50 values of 8.3, 6.0, 5.6, 5.6, 5.1, and 5.6, respectively. (S)-GSK-F1 has been shown to effectively inhibit hepatitis C virus (HCV) replication, making it a valuable tool for research in viral infections and signaling pathways. Its moderate pharmacokinetic profiles in rat models support its potential for in vivo studies.

    1 mg
    $55.00
    5 mg
    $115.00
    All 6 sizes
  • Pichromene
    Cat. No.
    A79818

    Pichromene

    Synonyms: S14161

    Pichromene is an anticancer agent that functions as a weak inhibitor of the phosphoinositide 3-kinase (PI3K) pathway. It has demonstrated effectiveness in inhibiting tumor growth in leukemia mouse models, making it a valuable tool for cancer research. This compound may provide insights into therapeutic strategies targeting PI3K-related signaling in malignancies.

    1 mg
    $125.00
    All 1 sizes
  • (S)-PI3K-IN-2
    Cat. No.
    A79819

    (S)-PI3K-IN-2

    (S)-PI3K-IN-2 is a selective inhibitor of phosphoinositide 3-kinase (PI3K) isoforms β and δ, exhibiting IC50 values of 0.198 μM and 0.282 μM, respectively. This compound effectively inhibits phosphorylation of AKT at serine 473 in MDA-MB-468 cancer cells, demonstrating an IC50 of 27 nM. (S)-PI3K-IN-2 is a valuable tool for investigating PI3K signaling pathways and their implications in cancer research.

    5 mg
    $470.00
    10 mg
    $805.00
    All 5 sizes
  • (R)-PI3Kδ-IN-15
    Cat. No.
    A79820

    (R)-PI3Kδ-IN-15

    (R)-PI3Kδ-IN-15 is the R-enantiomer of the selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, PI3Kδ-IN-15. This compound exhibits potent inhibition of PI3Kδ activity, which is critical in regulating immune cell functions and survival. It is primarily utilized in research focused on immune-related disorders and cancer therapies targeting the PI3Kδ pathway.

    5 mg
    $175.00
    10 mg
    $290.00
    All 4 sizes
  • (2S)-SB02024
    Cat. No.
    A79821

    (2S)-SB02024

    (2S)-SB02024 is a selective inhibitor of Vps34, targeting the phosphoinositide 3-kinase pathway. This compound plays a critical role in cellular processes such as autophagy and endocytosis, making it a valuable tool for research in cell biology and cancer studies. Its inhibition of Vps34 provides insights into the regulation of cellular signaling and membrane trafficking.

    1 mg
    $240.00
    5 mg
    $885.00
    All 2 sizes
  • PI3Kδ-IN-15
    Cat. No.
    A79822

    PI3Kδ-IN-15

    PI3Kδ-IN-15 is a highly selective inhibitor of the PI3Kδ isoform, demonstrating an IC50 of 0.5 nM specifically for the p110δ subunit. This compound exhibits over 30-fold greater potency against PI3Kδ compared to other isoforms including PI3Kγ, PI3Kβ, and PI3Kα. PI3Kδ-IN-15 is valuable for research applications targeting immune cell signaling and cancer biology, aiding in the exploration of therapeutic strategies for diseases associated with aberrant PI3Kδ activity.

    5 mg
    $195.00
    10 mg
    $315.00
    All 4 sizes
  • PI3Kδ-IN-9
    Cat. No.
    A79823

    PI3Kδ-IN-9

    PI3Kδ-IN-9 is a selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) with an IC50 value of 3.8 nM. It effectively modulates signaling pathways related to immune responses and inflammation. This compound is utilized in research applications focused on cancer, autoimmune diseases, and other conditions where PI3Kδ plays a critical role in cellular processes.

    5 mg
    $795.00
    All 1 sizes
  • Vps34-IN-3
    Cat. No.
    A79824

    Vps34-IN-3

    Vps34-IN-3 is a selective inhibitor of the VPS34 kinase, a key component of the phosphoinositide 3-kinase (PI3K) signaling pathway. This compound exhibits potent activity, making it suitable for research applications aimed at understanding lipid metabolism, autophagy, and cellular signaling processes. Its oral bioavailability enhances its utility in preclinical studies.

    Out of stock

    All 3 sizes
  • Nemiralisib hydrochloride
    Cat. No.
    A79825

    Nemiralisib hydrochloride

    Synonyms: GSK2269557

    Nemiralisib hydrochloride is a potent and highly selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) pathway, exhibiting a pKi of 9.9. This compound demonstrates significant biological activity in modulating immune responses and is primarily utilized in research related to cancer and autoimmune diseases. Its selective inhibition of PI3Kδ makes it a valuable tool for investigating the roles of this pathway in various cellular processes and therapeutic interventions.

    5 mg
    $90.00
    10 mg
    $150.00
    All 5 sizes
  • MDVN1003
    Cat. No.
    A79826

    MDVN1003

    MDVN1003 is a dual inhibitor of Bruton's tyrosine kinase (BTK) and phosphatidylinositol-3-kinase delta (PI3Kδ). This compound effectively inhibits B cell activation and blocks the phosphorylation of protein kinase B (AKT) as well as extracellular signal-regulated kinases 1 and 2 (ERK 1/2). MDVN1003 is primarily utilized in research related to non-Hodgkin’s lymphoma (NHL), offering insights into the underlying mechanisms of lymphocyte-driven malignancies.

    Out of stock

    All 3 sizes
  • PI3Kδ-IN-8
    Cat. No.
    A79827

    PI3Kδ-IN-8

    PI3Kδ-IN-8 is a selective inhibitor of phosphoinositide 3-kinase delta (PI3Kδ) with an IC50 value of 3.3 nM. It demonstrates a pronounced selectivity for PI3Kδ compared to PI3Kα, PI3Kβ, and PI3Kγ, exhibiting IC50 values of 377.2 nM, 241.6 nM, and 17.9 nM, respectively. This compound has shown significant anti-tumor activity, making it a valuable tool for research in cancer therapeutics and cellular signaling pathways involving PI3Kδ.

    5 mg
    $795.00
    All 1 sizes
  • GSK251
    Cat. No.
    A79828

    GSK251

    GSK251 is a potent and selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) isoform, exhibiting a novel binding mechanism. It demonstrates significant biological activity by effectively impeding PI3Kδ signaling pathways, which are crucial in various immune responses and hematological malignancies. GSK251 is utilized in research applications focused on understanding the role of PI3Kδ in cancer therapy and immune modulation.

    1 mg
    $135.00
    5 mg
    $340.00
    All 6 sizes
  • CHF-6523
    Cat. No.
    A79829

    CHF-6523

    CHF-6523 is a selective inhibitor of PI3Kδ, which plays a crucial role in cellular signaling pathways. This compound exhibits potent biological activity in modulating immune responses and has been employed in research focused on chronic obstructive pulmonary disease (COPD). Its ability to inhibit PI3Kδ makes it a valuable tool for investigating therapeutic strategies targeting immune and inflammatory processes associated with COPD.

    Out of stock

    All 3 sizes
  • PI3K-IN-9
    Cat. No.
    A79830

    PI3K-IN-9

    PI3K-IN-9 is a potent and selective inhibitor of PI3Kδ, demonstrating an IC50 of 8.9 nM. This compound effectively modulates PI3K signaling pathways, making it a valuable tool in research focused on cancer and immune responses. It is applicable in studies evaluating the role of PI3Kδ in various diseases, including hematological malignancies and inflammatory disorders.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3Kγ inhibitor 4
    Cat. No.
    A79831

    PI3Kγ inhibitor 4

    PI3Kγ Inhibitor 4 is a selective, orally bioavailable inhibitor targeting the phosphoinositide 3-kinase gamma (PI3Kγ) enzyme, demonstrating an IC50 of 40 nM. It exhibits notable selectivity ratios of approximately 7-fold, 43-fold, and 18-fold against the α, β, and δ isoforms, respectively. This compound is valuable for studying airway inflammation and may contribute to understanding associated pathological conditions.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3K-IN-63
    Cat. No.
    A79832

    PI3K-IN-63

    PI3K-IN-63 is a potent inhibitor of PI3Kα, exhibiting a Ki of 0.35 nM against human targets. This compound effectively inhibits the phosphorylation of AKT at the S473 site in cellular assays, demonstrating its capacity to interfere with critical signaling pathways. PI3K-IN-63 has shown efficacy in reducing the viability of non-small cell lung cancer cell lines harboring PIK3CA mutations, making it a valuable tool for research related to this type of cancer.

    25 mg
    $1,405.00
    50 mg
    $1,790.00
    All 3 sizes
  • Amdizalisib
    Cat. No.
    A79833

    Amdizalisib

    Synonyms: HMPL-689

    Amdizalisib is a selective inhibitor of the phosphoinositide 3-kinase (PI3K) pathway, which plays a crucial role in various cellular functions, including metabolism, growth, and survival. This compound demonstrates significant anti-proliferative effects in cancer cells and modulates immune responses, making it a valuable reagent for research applications focused on inflammatory diseases, autoimmune disorders, and oncology. Amdizalisib serves as an important tool for advancing the understanding of PI3K-related mechanisms in both disease states and therapeutic development.

    5 mg
    $795.00
    All 1 sizes
  • AM-8508
    Cat. No.
    A79834

    AM-8508

    AM-8508 is a potent PI3Kδ inhibitor, demonstrating an IC50 of 0.016 μM. It selectively targets PI3Kδ, effectively blocking AKT phosphorylation associated with B cell receptor signaling. Research has shown that AM-8508 suppresses the production of antigen-specific IgG and IgM in immunized rats, highlighting its potential applications in the study of inflammatory diseases. This compound serves as a valuable tool for investigating the role of PI3Kδ in immune responses.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • AM-1430
    Cat. No.
    A79835

    AM-1430

    AM-1430 is a highly selective and orally active inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) enzyme, with an IC50 value of 4.6 nM. This compound demonstrates significantly higher IC50 values for PI3Kα, PI3Kβ, and PI3Kγ, at 14.18 μM, 2.2 μM, and 3.22 μM, respectively. AM-1430 effectively inhibits B cell proliferation and shows strong in vivo activity, particularly in models of pAKT inhibition and hemoglobin (KLH) immune response. This reagent is suitable for research focused on inflammation and autoimmune diseases.

    Out of stock

    All 3 sizes
  • PI3Kα-IN-12
    Cat. No.
    A79836

    PI3Kα-IN-12

    PI3Kα-IN-12 is a highly selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα) with an IC50 of 1.2 nM. It demonstrates significant antiproliferative activity against HCT-116 and U87-MG cell lines, with IC50 values of 0.83 μM and 1.25 μM, respectively. In vivo, PI3Kα-IN-12 induces tumor regression in a U87-MG xenograft model at a dosage of 40 mg/kg administered intraperitoneally, making it a valuable tool for research on cancer therapy targeting the PI3K signaling pathway.

    Out of stock

    All 3 sizes
  • PI3Kα-IN-19
    Cat. No.
    A79837

    PI3Kα-IN-19

    PI3Kα-IN-19 is a selective inhibitor of PI3Kα, targeting the p110α catalytic subunit. This compound demonstrates significant biological activity in inhibiting the PI3Kα pathway, which is frequently dysregulated in various cancers. PI3Kα-IN-19 is valuable for researching cancer biology and evaluating therapeutic strategies that involve modulation of the PI3Kα signaling pathway.

    25 mg
    $1,655.00
    50 mg
    $2,115.00
    All 3 sizes
  • FAP-PI3KI1
    Cat. No.
    A79838

    FAP-PI3KI1

    FAP-PI3KI1 is a fibroblast-activated protein (FAP) inhibitor that selectively targets the phosphoinositide 3-kinase (PI3K) pathway in FAP-expressing human cells. This compound effectively inhibits collagen synthesis and reduces collagen deposition, making it a valuable tool for research in idiopathic pulmonary fibrosis (IPF) and related fibrotic conditions. Its targeted action facilitates investigating the role of the PI3K signaling pathway in fibrosis and offers potential insights into therapeutic strategies for IPF.

    Out of stock

    All 3 sizes
  • PI3K-IN-27
    Cat. No.
    A79839

    PI3K-IN-27

    PI3K-IN-27 is a targeted inhibitor of phosphoinositide 3-kinase (PI3K), a critical component in cellular signaling pathways that govern processes such as cell growth, differentiation, migration, and apoptosis. This compound exhibits potent inhibitory activity against PI3K, making it valuable for investigating hyper-proliferative diseases, including cancer and inflammation, as well as immune and autoimmune disorders. Its role in modulating PI3K activity underscores its potential utility in preclinical research settings.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • (S)-Zovegalisib
    Cat. No.
    A79840

    (S)-Zovegalisib

    Synonyms: (S)-RLY-2608

    (S)-Zovegalisib, the S-enantiomer of RLY-2608, is a novel allosteric inhibitor of PI3Kα, selectively targeting mutant forms of the enzyme. It demonstrates potent anti-tumor activity, making it a valuable compound for cancer research. This reagent is particularly useful in studies focused on the role of PI3Kα mutations in tumorigenesis and therapeutic responses.

    5 mg
    $330.00
    10 mg
    $545.00
    All 5 sizes

Items 326-350 of 411

Added to your cart

View Cart Checkout

    Loading...